Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor β1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat

Arie Erman*, Semyon Veksler, Uzi Gafter, Geoffrey Boner, Clara Wittenberg, David Jonathan van Dijk

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Combination therapy with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) is used to improve renal outcome achieved by monotherapy in diabetic patients. In addition, interference with the renin-angiotensin system (RAS) reduced expression and excretion of transforming growth factor β1 (TGF-β1) in diabetic nephropathy. The aim of this study was to investigate the effects of interrupting the RAS by ACE inhibitor (ACE-I) or ARB monotherapy or by combination therapy on proteinuria, kidney hypertrophy and plasma TGF-β1 in diabetic rats.

Original languageEnglish
Pages (from-to)146-151
Number of pages6
JournalJRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Volume5
Issue number3
DOIs
StatePublished - Sep 2004

Keywords

  • ACE-I
  • ARB
  • Diabetis mellitus
  • Proteinuria
  • Renin-angiotensin system
  • TGF-β1

Fingerprint

Dive into the research topics of 'Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor β1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat'. Together they form a unique fingerprint.

Cite this